---
title: Macrocyclics, Inc. vs 重庆兴泰濠制药有限公司 (Sintaho)
slug_a: macrocyclics
slug_b: sintaho
site: cdmo
review_signal_gate: closed
canonical_path: /compare/macrocyclics/sintaho
generated_by: BioBM Editorial AI
---

# Macrocyclics, Inc. vs 重庆兴泰濠制药有限公司 (Sintaho)

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Macrocyclics, Inc. (macrocyclics) is listed for cdmo. Chelator-focused CDMO for radiopharmaceuticals, offering cGMP clinical-trial manufacture, custom synthesis scaled to kilogram quantities, bioconjugation, and HPLC/Q-TOF analytical testing.

Services: 5. Modalities: 3. Indications: 1. Locations: 0. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (5).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

重庆兴泰濠制药有限公司 (Sintaho) (sintaho) is listed for cdmo. China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.

Services: 4. Modalities: 2. Indications: 0. Locations: 1. Certifications: 1. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (4).

Review summary: Review summary withheld until site-level review gate opens.